BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Griffin AM, Kahlig KM, Hatch RJ, Hughes ZA, Chapman ML, Antonio B, Marron BE, Wittmann M, Martinez-Botella G. Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and In Vivo Activity of an Oxadiazole Series. ACS Med Chem Lett 2021;12:593-602. [PMID: 33859800 DOI: 10.1021/acsmedchemlett.0c00675] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu R, Sun L, Wang Y, Wang Q, Wu J. New use for an old drug: quinidine in KCNT1-related epilepsy therapy. Neurol Sci 2022. [DOI: 10.1007/s10072-022-06521-x] [Reference Citation Analysis]
2 Qunies AM, Mishra NM, Spitznagel BD, Du Y, Acuña VS, David Weaver C, Emmitte KA. Structure-activity relationship studies in a new series of 2-amino-N-phenylacetamide inhibitors of Slack potassium channels. Bioorganic & Medicinal Chemistry Letters 2022. [DOI: 10.1016/j.bmcl.2022.129013] [Reference Citation Analysis]
3 M Qunies A, A Emmitte K. Small-molecule inhibitors of Slack potassium channels as potential therapeutics for childhood epilepsies. Pharm Pat Anal 2022. [PMID: 35369761 DOI: 10.4155/ppa-2022-0002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cole BA, Pilati N, Lippiat JD. Epilepsy-causing KCNT1 variants increase KNa1.1 channel activity by disrupting the activation gate.. [DOI: 10.1101/2021.09.16.460601] [Reference Citation Analysis]
5 Cole BA, Clapcote SJ, Muench SP, Lippiat JD. Targeting KNa1.1 channels in KCNT1-associated epilepsy. Trends Pharmacol Sci 2021;42:700-13. [PMID: 34074526 DOI: 10.1016/j.tips.2021.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]